{"api":"v1","generated_at":"2026-09-16T00:00:55.992Z","licence":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/","attribution":"TOLL, with a link to the page cited"},"page":"https://tollindex.com/e/clinicalintelpulse-theaslangroupllc-com-api-clinical-approval-outlook-3758a3","pinned_page":"https://tollindex.com/e/clinicalintelpulse-theaslangroupllc-com-api-clinical-approval-outlook-3758a3/at/2026-09-15T21-20Z","pinned":false,"method":"https://tollindex.com/ledger/method","snapshot_at":"2026-09-15T21:20:12.737Z","snapshot_stamp":"2026-09-15T21-20Z","endpoint":{"slug":"clinicalintelpulse-theaslangroupllc-com-api-clinical-approval-outlook-3758a3","canonical_url":"https://clinicalintelpulse.theaslangroupllc.com/api/clinical/approval-outlook","resource":"https://clinicalintelpulse.theaslangroupllc.com/api/clinical/approval-outlook","http_method":"GET","type":"http","x402_version":2,"registries":["cdp","binance"],"primary_registry":"cdp","curated_by_coinbase":false,"description":"FDA/EMA drug approval probability + PDUFA calendar for a disease area — which Phase 3 drugs are most likely to win approval in 12-24 months, with mechanism, trial results, approval-probability scores and historical phase-3 success rates. Worldwide. For biotech-investing and payer agents.","service_name":"ClinicalIntelPulse","declared_category":null,"declared_tags":["fda-approval","pdufa","ema","phase-3","drug-approval"],"route_template":null,"registry_updated":"2026-08-20T14:01:56.863Z"},"derived":{"note":"fields no registry supplies; TOLL derives them and marks them derived on the page","title":"clinical approval outlook","category":"inference","first_observed_by_toll":"2026-09-10T19:08:24.178Z","last_observed_by_toll":"2026-09-15T21:20:12.737Z","observation_began":"2026-09-10"},"presence":{"listed_now":true,"first_absent_at":null,"delisting_confirmed_at":null,"events":[{"registry":"binance","at":"2026-09-10T19:08:24.178Z","event":"listed"},{"registry":"cdp","at":"2026-09-10T19:08:24.178Z","event":"listed"}]},"accepts":[{"registry":"cdp","ordinal":0,"network":"eip155:8453","asset":"0x833589fcd6edb6e08f4c7c32d4f71b54bda02913","asset_name":"USD Coin","symbol":"USDC","decimals":6,"amount_display":"0.25 USDC","amount_units":0.25,"decimals_known":true,"pay_to":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","scheme":"exact"},{"registry":"cdp","ordinal":1,"network":"eip155:8453","asset":"0x833589fcd6edb6e08f4c7c32d4f71b54bda02913","asset_name":"GatewayWalletBatched","symbol":"USDC","decimals":6,"amount_display":"0.25 USDC","amount_units":0.25,"decimals_known":true,"pay_to":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","scheme":"exact"},{"registry":"cdp","ordinal":2,"network":"solana:5eykt4UsFv8P8NJdTREpY1vzqKqZKvdp","asset":"EPjFWdd5AufqSSqeM2qN1xzybapC8G4wEGGkZwyTDt1v","asset_name":null,"symbol":"USDC","decimals":6,"amount_display":"0.25 USDC","amount_units":0.25,"decimals_known":true,"pay_to":"985iFjbnGQ3dJcwXnfRCMSrH4Jnc3kW1N6msR64B5KX1","scheme":"exact"},{"registry":"cdp","ordinal":3,"network":"eip155:137","asset":"0x3c499c542cef5e3811e1192ce70d8cc03d5c3359","asset_name":"USD Coin","symbol":"USDC","decimals":6,"amount_display":"0.25 USDC","amount_units":0.25,"decimals_known":true,"pay_to":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","scheme":"exact"},{"registry":"cdp","ordinal":4,"network":"eip155:42161","asset":"0xaf88d065e77c8cc2239327c5edb3a432268e5831","asset_name":"USD Coin","symbol":"USDC","decimals":6,"amount_display":"0.25 USDC","amount_units":0.25,"decimals_known":true,"pay_to":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","scheme":"exact"},{"registry":"cdp","ordinal":5,"network":"eip155:480","asset":"0x79a02482a880bce3f13e09da970dc34db4cd24d1","asset_name":"USDC","symbol":null,"decimals":null,"amount_display":"250000 smallest units, decimals unknown","amount_units":null,"decimals_known":false,"pay_to":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","scheme":"exact"},{"registry":"cdp","ordinal":6,"network":"eip155:143","asset":"0x754704bc059f8c67012fed69bc8a327a5aafb603","asset_name":"USDC","symbol":null,"decimals":null,"amount_display":"250000 smallest units, decimals unknown","amount_units":null,"decimals_known":false,"pay_to":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","scheme":"exact"},{"registry":"cdp","ordinal":7,"network":"eip155:196","asset":"0x779ded0c9e1022225f8e0630b35a9b54be713736","asset_name":"USD₮0","symbol":null,"decimals":null,"amount_display":"250000 smallest units, decimals unknown","amount_units":null,"decimals_known":false,"pay_to":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","scheme":"exact"},{"registry":"cdp","ordinal":8,"network":"eip155:999","asset":"0xb88339cb7199b77e23db6e890353e22632ba630f","asset_name":"USDC","symbol":null,"decimals":null,"amount_display":"250000 smallest units, decimals unknown","amount_units":null,"decimals_known":false,"pay_to":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","scheme":"exact"},{"registry":"cdp","ordinal":9,"network":"algorand:wGHE2Pwdvd7S12BL5FaOP20EGYesN73k","asset":"31566704","asset_name":null,"symbol":null,"decimals":null,"amount_display":"250000 smallest units, decimals unknown","amount_units":null,"decimals_known":false,"pay_to":"62A253YPATFNJCPRKID3FKD77MYJFNTVRYRP4B4JWG36EGLPY7UXFWGI7I","scheme":"exact"},{"registry":"cdp","ordinal":10,"network":"xrpl:0","asset":"XRP","asset_name":null,"symbol":null,"decimals":null,"amount_display":"250000 smallest units, decimals unknown","amount_units":null,"decimals_known":false,"pay_to":"rMnHeutYALco8RYFVcmuU4BCgSzBpPEh32","scheme":"exact"},{"registry":"cdp","ordinal":11,"network":"xrpl:0","asset":"524C555344000000000000000000000000000000","asset_name":null,"symbol":null,"decimals":null,"amount_display":"amount not declared","amount_units":null,"decimals_known":false,"pay_to":"rMnHeutYALco8RYFVcmuU4BCgSzBpPEh32","scheme":"exact"},{"registry":"cdp","ordinal":12,"network":"eip155:56","asset":"0x8d0d000ee44948fc98c9b98a4fa4921476f08b0d","asset_name":"World Liberty Financial USD","symbol":null,"decimals":null,"amount_display":"250000000000000000 smallest units, decimals unknown","amount_units":null,"decimals_known":false,"pay_to":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","scheme":"exact"},{"registry":"binance","ordinal":0,"network":"eip155:56","asset":"0x8d0d000ee44948fc98c9b98a4fa4921476f08b0d","asset_name":null,"symbol":null,"decimals":null,"amount_display":"250000000000000000 smallest units, decimals unknown","amount_units":null,"decimals_known":false,"pay_to":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","scheme":"eip3009"}],"counters":{"observed_at":"2026-09-15T21:20:12.737Z","calls_30d":2,"unique_payers_30d":1,"last_called_at":"2026-08-20T14:01:56.591Z"},"validation":{"latest":{"observed_at":"2026-09-15T04:26:20.866Z","state":"pass","failed_checks":[],"endpoint_http_status":402,"run_id":"daily-2026-09-15"},"uptime":[{"days":7,"observed":5,"passed":5,"ratio":1},{"days":30,"observed":5,"passed":5,"ratio":1},{"days":90,"observed":5,"passed":5,"ratio":1}],"history_90d":[{"observed_at":"2026-09-15T04:26:20.866Z","state":"pass","failed_checks":[],"run_id":"daily-2026-09-15","state_changed":false},{"observed_at":"2026-09-14T04:23:02.399Z","state":"pass","failed_checks":[],"run_id":"daily-2026-09-14","state_changed":false},{"observed_at":"2026-09-13T04:21:53.799Z","state":"pass","failed_checks":[],"run_id":"daily-2026-09-13","state_changed":false},{"observed_at":"2026-09-12T06:37:33.497Z","state":"pass","failed_checks":[],"run_id":"daily-2026-09-12","state_changed":false},{"observed_at":"2026-09-11T10:08:07.554Z","state":"pass","failed_checks":[],"run_id":"daily-2026-09-11","state_changed":true}]},"seller":{"wallet":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","page":"https://tollindex.com/seller/0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","endpoints":964,"hosts":78},"reports":0,"registry_record":{"cdp":[{"tags":["fda-approval","pdufa","ema","phase-3","drug-approval"],"type":"http","accepts":[{"asset":"0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913","extra":{"name":"USD Coin","version":"2"},"payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","amount":"250000","scheme":"exact","network":"eip155:8453","maxTimeoutSeconds":300},{"asset":"0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913","extra":{"name":"GatewayWalletBatched","version":"1","verifyingContract":"0x77777777dcc4d5a8b6e418fd04d8997ef11000ee"},"payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","amount":"250000","scheme":"exact","network":"eip155:8453","maxTimeoutSeconds":604900},{"asset":"EPjFWdd5AufqSSqeM2qN1xzybapC8G4wEGGkZwyTDt1v","extra":{"feePayer":"BENrLoUbndxoNMUS5JXApGMtNykLjFXXixMtpDwDR9SP"},"payTo":"985iFjbnGQ3dJcwXnfRCMSrH4Jnc3kW1N6msR64B5KX1","amount":"250000","scheme":"exact","network":"solana:5eykt4UsFv8P8NJdTREpY1vzqKqZKvdp","maxTimeoutSeconds":300},{"asset":"0x3c499c542cEF5E3811e1192ce70d8cC03d5c3359","extra":{"name":"USD Coin","version":"2"},"payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","amount":"250000","scheme":"exact","network":"eip155:137","maxTimeoutSeconds":300},{"asset":"0xaf88d065e77c8cC2239327C5EDb3A432268e5831","extra":{"name":"USD Coin","version":"2"},"payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","amount":"250000","scheme":"exact","network":"eip155:42161","maxTimeoutSeconds":300},{"asset":"0x79A02482A880bCe3F13E09da970dC34dB4cD24D1","extra":{"name":"USDC","version":"2"},"payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","amount":"250000","scheme":"exact","network":"eip155:480","maxTimeoutSeconds":300},{"asset":"0x754704Bc059F8C67012fEd69BC8A327a5aafb603","extra":{"name":"USDC","version":"2"},"payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","amount":"250000","scheme":"exact","network":"eip155:143","maxTimeoutSeconds":300},{"asset":"0x779ded0c9e1022225f8e0630b35a9b54be713736","extra":{"name":"USD₮0","version":"1"},"payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","amount":"250000","scheme":"exact","network":"eip155:196","maxTimeoutSeconds":300},{"asset":"0xb88339CB7199b77E23DB6E890353E22632Ba630f","extra":{"name":"USDC","version":"2"},"payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","amount":"250000","scheme":"exact","network":"eip155:999","maxTimeoutSeconds":300},{"asset":"31566704","extra":{"feePayer":"ZMFK2OI7ZBD2U27ISERZC4S6LKM6WMFJPZQ4MYNJDZ2VNBNMBA67RA22AA"},"payTo":"62A253YPATFNJCPRKID3FKD77MYJFNTVRYRP4B4JWG36EGLPY7UXFWGI7I","amount":"250000","scheme":"exact","network":"algorand:wGHE2Pwdvd7S12BL5FaOP20EGYesN73k","maxTimeoutSeconds":300},{"asset":"XRP","extra":{"invoiceId":"66F61C2463034AEC9E907708F6A8148D","sourceTag":804681468},"payTo":"rMnHeutYALco8RYFVcmuU4BCgSzBpPEh32","amount":"250000","scheme":"exact","network":"xrpl:0","maxTimeoutSeconds":300},{"asset":"524C555344000000000000000000000000000000","extra":{"issuer":"rMxCKbEDwqr76QuheSUMdEGf4B9xJ8m5De","invoiceId":"B5888DBDE76D40729638A804FA06FE18","sourceTag":804681468},"payTo":"rMnHeutYALco8RYFVcmuU4BCgSzBpPEh32","amount":"0.25","scheme":"exact","network":"xrpl:0","maxTimeoutSeconds":300},{"asset":"0x8d0D000Ee44948FC98c9B98A4FA4921476f08B0d","extra":{"name":"World Liberty Financial USD","version":"1","signerAddress":"0x34F7a661160780Ce1346e6D7B96D2bE244590899","assetTransferMethod":"eip3009"},"payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","amount":"250000000000000000","scheme":"exact","network":"eip155:56","maxTimeoutSeconds":300}],"quality":{"lastCalledAt":"2026-08-20T14:01:56.591Z","l30DaysTotalCalls":2,"l30DaysUniquePayers":1},"resource":"https://clinicalintelpulse.theaslangroupllc.com/api/clinical/approval-outlook","extensions":{"bazaar":{"info":{"input":{"type":"http","method":"GET","queryParams":{"lang":"en | es | fr | de | ja | zh | ko | pt | ar | hi (default: en)","agency":"FDA | EMA | both (default: both)","horizon":"12m | 18m | 24m (default: 18m)","condition":"Disease area — e.g. \"Alzheimer Disease\" | \"Multiple Myeloma\" | \"NASH\" | \"Heart Failure\" | \"Obesity\""}},"output":{"type":"json","example":{"query_summary":{"horizon":"18m","agencies":["FDA","EMA"],"condition":"Alzheimer Disease"},"market_context":"Alzheimer's is the highest-value CNS approval category. Any successful amyloid or tau therapy represents $5-15B peak sales potential.","pdufa_calendar":[{"drug":"Donanemab","sponsor":"Eli Lilly","indication":"Early symptomatic AD","pdufa_date":"2025-Q2","priority_review":true}],"approval_candidates":[{"drug":"Lecanemab (Leqembi)","nctId":"NCT03887455","sponsor":"Eisai / Biogen","key_risk":"ARIA (amyloid-related imaging abnormalities) safety profile limiting real-world use","mechanism":"Anti-amyloid monoclonal antibody (protofibrils)","ema_status":"CHMP assessment ongoing 2025","fda_status":"Full approval received 2023; expanded label applications pending","trial_result":"Positive — 27% slowing of clinical decline vs placebo (p<0.001)","approval_probability":85}],"approval_rate_context":{"rare_disease_premium":"Breakthrough therapy designation adds ~15% probability uplift","us_approval_rate_phase3_pct":58,"disease_area_historical_phase3_success_pct":55}}}},"schema":{"type":"object","$schema":"https://json-schema.org/draft/2020-12/schema","required":["input"],"properties":{"input":{"type":"object","required":["type","method"],"properties":{"type":{"type":"string","const":"http"},"method":{"enum":["GET","HEAD","DELETE"],"type":"string"},"queryParams":{"type":"object","properties":{"lang":{"type":"string"},"agency":{"type":"string"},"horizon":{"type":"string"},"condition":{"type":"string"}}}},"additionalProperties":false},"output":{"type":"object","required":["type"],"properties":{"type":{"type":"string"},"example":{"type":"object"}}}}}},"builder-code":{"info":{"a":"bc_gxy6qn5p"},"schema":{"type":"object","$schema":"https://json-schema.org/draft/2020-12/schema","properties":{"a":{"type":"string","pattern":"^[a-z0-9_]{1,32}$","description":"App builder code"},"s":{"type":"array","items":{"type":"string","pattern":"^[a-z0-9_]{1,32}$"},"description":"Service builder codes"},"w":{"type":"string","pattern":"^[a-z0-9_]{1,32}$","description":"Wallet builder code"}},"additionalProperties":false}}},"description":"FDA/EMA drug approval probability + PDUFA calendar for a disease area — which Phase 3 drugs are most likely to win approval in 12-24 months, with mechanism, trial results, approval-probability scores and historical phase-3 success rates. Worldwide. For biotech-investing and payer agents.","lastUpdated":"2026-08-20T14:01:56.863Z","serviceName":"ClinicalIntelPulse","x402Version":2}],"binance":[{"type":"http","accepts":[{"asset":"0x8d0D000Ee44948FC98c9B98A4FA4921476f08B0d","payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","scheme":"eip3009","network":"eip155:56","maxAmountRequired":"250000000000000000"}],"resource":"https://clinicalintelpulse.theaslangroupllc.com/api/clinical/approval-outlook","description":"FDA/EMA drug approval probability + PDUFA calendar for a disease area — which Phase 3 drugs are most likely to win approval in 12-24 months, with mechanism, trial results, approval-probability scores and historical phase-3 success rates. Worldwide. For biotech-investing and payer agents.","lastUpdated":1787408230043,"x402Version":2}]}}